Form 4: Oramed Pharmaceuticals COO Joshua Hexter Reports Acquisition of Common Stock Through PSU Settlement

Joshua Hexter, COO & CBO of Oramed Pharmaceuticals, reports the acquisition of common stock following the settlement of performance stock units (PSUs).

Summary

• On February 11, 2025, Joshua Hexter, the COO & CBO of Oramed Pharmaceuticals, reported the acquisition of common stock.
• These shares were obtained through the settlement of performance stock units (PSUs) that had vested.
• The PSUs were previously granted on January 4, 2024, January 2, 2025, and February 3, 2025.
• Mr. Hexter acquired 45,000 shares, 48,500 shares, and 33,334 shares from the settlement of these PSUs respectively.
• Following these transactions, Mr. Hexter's total direct ownership of common stock in Oramed Pharmaceuticals increased to 833,167 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reflects the vesting of PSUs and subsequent acquisition of shares, which is a standard part of executive compensation. The fact that performance criteria were met is mildly positive.

Positives

• The vesting of PSUs indicates that performance criteria were met, which could be a positive sign for the company's performance.
• Increased insider ownership can sometimes be seen as a positive signal, aligning management's interests with those of shareholders.

Industry Context

This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the ownership changes of company executives.

Stakeholder Impact

• The increased insider ownership could be viewed positively by shareholders, as it aligns management's interests with theirs.

Key Dates